Nonalcoholic Steatohepatitis Therapeutics Market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
issue, as obese patients who suffer from NFALD or NASH are<br />
also likely to suffer from high blood cholesterol and diabetes.<br />
Apart from obesity, patients of glucose intolerance and<br />
dyslipidemia are also prone to suffer from NFALD and NASH.<br />
There is no clear link that points to the reason NFALD occurs,<br />
but it is currently suggested that insulin resistance has a major<br />
role to play in it. In spite of the severity of the disease, patients<br />
are largely asymptomatic until complications arise. Therefore,<br />
the best preventive measure against NFALD and NASH is to<br />
lead a healthy life and moderate alcohol consumption.<br />
The key players in this market that are expected to play a major<br />
role in the market’s immediate future include Tobira<br />
<strong>Therapeutics</strong>, Inc., Conatus Pharmaceuticals, Immuron Ltd.,<br />
Zydus Cadila, Gilead Sciences, Inc., GENFIT SA, Galmed<br />
Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., and<br />
Astazeneca Plc.<br />
Browse Full Press Release on <strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong><br />
<strong>Therapeutics</strong> <strong>Market</strong>:<br />
Press Release
Change language